System1, Inc. reported its financial results for the third quarter ended September 30, 2026, disclosing revenue of $25.95 million. The company recorded a significant net loss of $51.28 million for the quarter, impacted by a $63.6 million impairment charge on goodwill and other long-lived assets.
For the nine months ended September 30, 2026, Longeveron Inc. reported a net loss of $16.9 million, a slight improvement from the $17.3 million loss in the prior year period. Total revenues decreased slightly to $0.8 million, while the company strengthened its cash position to $7.2 million through private placements and warrant exercises.
Birchtech Corp. reported a net loss of $4.6 million for the nine months ended September 30, 2026, compared to a $2.4 million loss in the prior year period, despite a 23% increase in product revenue. The company significantly strengthened its balance sheet during the period, ending with $10.8 million in cash following a common stock issuance that raised approximately $14.2 million in net proceeds.
Franklin Covey Co. reported fiscal 2026 consolidated revenue of $261.5 million, a 2% decrease from the prior year, while net income improved to $4.9 million. Despite lower revenues in the Enterprise Division due to macroeconomic uncertainties and geopolitical tensions, Adjusted EBITDA increased slightly to $28.9 million, supported by restructuring activities and cost reduction efforts.
Holistic Asset Finance Group Co., Ltd. reported a significant increase in revenue to $4.94 million for the nine months ended September 30, 2026, compared to $1.69 million in the prior year. The company achieved a small net income of $2,436 for the period, recovering from a net loss of $36,331 in 2025, primarily driven by its export trading and marketing services operations.
AnaptysBio reported financial results for the fiscal first quarter ended September 30, 2026, highlighted by $1.0 billion in global net sales of Jemperli for the first nine months of 2026. The company is currently awaiting a court judgment in its litigation against GSK and Tesaro, where it is seeking the reversion of Jemperli rights as a remedy.
Counterparty
GSK
“Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications.”
Daniel Faga, president and chief executive officer
“We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026.”
Daniel Faga, president and chief executive officer
Polaryx Therapeutics reported a net loss of $7.3 million for the nine months ended September 30, 2026, compared to $7.5 million in the prior year period. The company maintains a going concern warning due to recurring losses and negative operating cash flows, though it successfully raised $9.8 million through common stock issuances during the period.
MultiSensor AI Holdings reported Q3 2026 financial results, highlighted by a 43% increase in software revenue which now represents 58% of total revenue. The company reported a net loss of $1.9 million on total revenue of $1.5 million, while maintaining a debt-free balance sheet with $20.4 million in cash.
Term
Q3 2026
“Our relationship with our largest distribution customer shows how we believe this business scales. Programs that began in Europe continue to grow, with solar performance monitoring now extending to additional European sites, and have led to that customer’s first 14-site rollout in North America. Each step has been built on results their maintenance teams have seen in their own facilities, and we are seeing that same path open up with customers like Manchester Airports Group.”
Asim Akram, Chief Executive Officer
“Our revenue mix is shifting the way we intended. Software subscriptions are now the majority of our revenue for the quarter, and recurring revenue continues to grow, which gives us better visibility into the periods ahead. We paired that with disciplined spending, and with help from strong collections our cash use slowed meaningfully in the third quarter. With no debt, we have the balance sheet to keep investing in recurring revenue.”
Beeline Holdings, Inc. reported a net loss of $13.1 million for the nine months ended September 30, 2026, compared to a $15.0 million loss in the prior year period. Total net revenues grew significantly to $8.3 million from $5.3 million, driven by higher gains on loan sales and origination fees, though operating expenses also increased to $21.8 million.
Marpai, Inc. reported a net loss of $11.1 million for the nine months ended September 30, 2026, with revenue declining to $13.0 million from $14.1 million in the prior year period. The company improved its stockholders' deficit to $29.8 million, aided by the issuance of $12.1 million in privately placed preferred stock.
Horizon Kinetics Holding Corp reported a net loss attributable to the company of $18.35 million for the third quarter of 2026, compared to a net income of $7.24 million in the prior year period. Total revenue remained relatively flat at $18.03 million, but the bottom line was significantly impacted by investment losses within consolidated investment products and unrealized losses on investments.
ProKidney Corp. reported a net loss available to Class A common stockholders of $84.1 million for the nine months ended September 30, 2026, compared to $49.8 million in the prior year period. The increase in loss was primarily driven by higher research and development expenses, which rose to $110.8 million as the company continues its clinical programs.
Energous Corporation reported Q3 2026 revenue of $3.4 million, a 167% increase year-over-year, driven by commercial adoption of its wireless power technology. Year-to-date revenue of $9.6 million has already surpassed the company's total revenue for the full year 2025. The company reported a GAAP net loss of $2.5 million for the quarter while noting significant improvements in gross margin as production scales.
Term
Q3 2026
“Our third quarter results reflect continued momentum in the commercial adoption of Energous’ technology, with revenue growing significantly year over year and our year-to-date revenue performance already surpassing full-year 2025.”
Mallorie Burak, CEO and CFO of Energous
“We also made meaningful progress in improving gross margins as we continue to scale production to better support customer demand. Looking ahead, we see significant opportunity to build on this momentum as enterprises increasingly recognize the value of continuous, real-time visibility into their operations.”
Atrium Therapeutics reported third quarter 2026 financial results, highlighting the dosing of the first patient in its Phase 1/2 clinical trial for ATR 1072. The company also closed a $50 million private placement, extending its cash runway through 2028 with a pro-forma cash balance of $293.6 million.
Term
Q3 2026
“The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome.”
Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics
“Our $50 million private placement with leading institutional investors extends our cash runway through 2028. With ~$290 million on our balance sheet, we are well positioned to deliver on our upcoming milestones.”
Brendan Winslow, Chief Financial Officer of Atrium Therapeutics
Blackstone Private Real Estate Credit and Income Fund reported total assets of $2.57 billion as of September 30, 2026, a significant increase from $1.58 billion at year-end 2025. Net investment income for the nine months ended September 30, 2026, was $65.3 million, driven by interest income from its growing portfolio of senior loans and debt securities.
ADARx Pharmaceuticals reported a significant increase in cash and cash equivalents to $570.6 million as of September 30, 2026, following its initial public offering and concurrent private placement. The company is advancing a clinical pipeline including onvuzosiran (Phase 3) and agazisiran (Phase 2), supported by a major collaboration with AbbVie that contributed to $326.4 million in total deferred revenue.
Once Upon a Farm, PBC reported net sales of $247.2 million for the nine months ended September 30, 2026, a significant increase from $176.7 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $24.6 million for the first nine months of 2026, though this was an improvement over the $39.8 million net loss reported for the same period in 2025.
As of September 30, 2026, SKYX Platforms Corp. reported a significant increase in cash and cash equivalents to $19.4 million, up from $8.1 million at the end of 2025. Total assets grew to $63.3 million, while total liabilities decreased to $49.3 million, primarily driven by reductions in operating lease liabilities and convertible notes.
Vylor Inc. (formerly the Seed Business of Corteva) became an independent public company on October 1, 2026, following a tax-free spin-off. For the nine months ended September 30, 2026, the company reported net sales of $13,742 million and net income attributable to the company of $1,311 million, compared to $13,491 million and $1,646 million respectively in the prior year period.
AmpliTech Group reported Q3 2026 revenue of $6.58 million, an 8.0% increase year-over-year, driven by strong growth in its Spectrum Semiconductor Materials distribution business. The company narrowed its net loss sequentially to $1.89 million and reported a significant backlog surpassing $52 million as of October 2026.
VolitionRx reported financial results for the third quarter of 2026, highlighting progress in its Nu.Q platform across sepsis, lung cancer, and veterinary diagnostics. The company noted the launch of the French government-funded DETECSEPS program and active licensing discussions for its Capture-Seq technology in the liquid biopsy market.
Term
Q3 2026
“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”
Cameron Reynolds, President and Group Chief Executive Officer
Tenon Medical reported third quarter 2026 revenue of $1.4 million, a 22% increase year-over-year, driven by the commercial launch of its 3D-printed lateral screw for the SImmetry+ system. The company strengthened its balance sheet by raising $15.6 million in gross proceeds, repaying $5.12 million in convertible notes, and ending the quarter with $8.3 million in cash.
Vyome Holdings reported a net loss of $2.64 million for the nine months ended September 30, 2026, a significant improvement from the $9.20 million loss in the prior year period which was impacted by high transactional fees. The company strengthened its cash position to $6.96 million through ATM financing activities, while research and development expenses increased substantially to $1.58 million.
GCT Semiconductor reported Q3 2026 financial results with revenue increasing 148.6% year-over-year to $1.1 million. The company highlighted that year-to-date 5G chipset shipments exceeded 11,300 units and expanded its addressable market into terrestrial-based location services.
Term
Q3 2026
“We continued to make progress across our 5G customer programs in the third quarter, advancing integration and certification work with existing customers while expanding the range of applications our 5G chipsets can serve.”
Assembly Biosciences, Inc. is a non-accelerated filer and smaller reporting company focused on therapeutic product candidates, primarily through a collaboration with Gilead Sciences. As of September 30, 2026, the company remains pre-revenue and unprofitable, relying on third-party CROs and collaborators for clinical development and manufacturing.
Rocket Pharmaceuticals reported third quarter 2026 financial results, highlighting FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease with dosing completion expected by mid-2027. The company ended the quarter with $279.4 million in cash and investments, which is expected to fund operations into the third quarter of 2028.
Term
Q3 2026
“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027. We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM. Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children. Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
QXO, Inc. reported third quarter 2026 financial results, including net sales of $4.9 billion and an adjusted EBITDA of $557 million. The results reflect the integration of legacy Beacon, Kodiak, and TopBuild businesses, with management targeting $50 billion in annual revenue within the decade. Additionally, the Board of Directors authorized a new $500 million common stock repurchase program.
“Our organic daily revenue trends improved for the second consecutive quarter despite a soft construction market. Companywide pricing increased 2.2% year over year. We’re prioritizing higher-margin products; in Roofing and Waterproofing, complementary product sales grew 4.2%, and TRI-BUILT reached a record 10.6% of sales. Mechanical insulation distribution revenue grew 16%, supported by strong data center demand.”
Brad Jacobs, chairman and chief executive officer of QXO
“We’re on track to reach $4 billion in adjusted EBITDA by 2030 from the businesses we already own and $50 billion in annual revenue within the decade through organic growth and disciplined acquisitions.”
Brad Jacobs, chairman and chief executive officer of QXO
ARC Group Acquisition I Corp. reported a net income of $1,318,548 for the nine months ended September 30, 2026, primarily driven by $1,822,314 in interest income from its trust account. The company completed its initial public offering in May 2026, resulting in $122,572,314 held in trust and 12,075,000 Class A ordinary shares subject to possible redemption.
NeoVolta reported financial results for the quarter ended September 30, 2026, showing a sequential revenue rebound to $2.8 million driven by its residential third-party ownership (TPO) platform. The company also highlighted a $116 million Master Purchase Agreement for utility-scale products and a strategic 9 GWh battery cell supply collaboration with SK On.
Equillium, Inc. reported a net loss of $4.6 million for the third quarter of 2026, with cash and cash equivalents increasing to $53.3 million as of September 30, 2026, following a private placement. Subsequent to the quarter-end, the company raised an additional $20.0 million in gross proceeds, which management believes will fund operations for at least the next 12 months.